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Objective: Economic evaluation remains an understudied aspect of lower extremity vascular reconstructions. This study
reviewed the economic-based literature with respect to open and endovascular treatment of peripheral arterial disease.
Methods: This systematic review included economic analyses of open and endovascular treatment of lower extremity
peripheral arterial disease, including claudication and critical limb ischemia. Studies were categorized as model-based,
cost-consequences, or econometric cost-analyses. Clinical, financial, and time-based outcomes were examined.
Results: From a candidate list of 1351 studies, 19 were appropriate for the review, comprising 3 model-based, 12
cost-consequence, and 4 cost-analyses. Because of the small numbers, claudication and critical limb ischemia studies were
analyzed together. There was a trend favoring initial cost-savings with endovascular therapy. Whether this benefit is
sustained over time is unknown. We were prevented from drawing cost-efficacy inferences because of a noted lack of
standardized patient-centric outcomes, longitudinal data, and reintervention data.
Conclusions: The existing lower extremity arterial revascularization economic literature is inadequate for drawing
cost-efficacy conclusions and cannot inform guidelines for open vs endovascular treatment. Overcoming this limitation
will require the inclusion of cost (initial and reintervention) and patient-centric outcomes in future studies evaluating
lower extremity revascularization technologies. All journals, particularly vascular journals, should enforce standard
reporting guidelines of effectiveness and economic studies to enable appropriate comparative and cost-effectiveness
analyses. ( J Vasc Surg 2011;54:1131-44.)
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aTechnologic advances have resulted in the widespread
application of less invasive percutaneous interventions in
patients with lower extremity peripheral arterial disease
(PAD).1 There are many reported benefits to such an
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doi:10.1016/j.jvs.2011.04.058pproach compared with the traditional strategy of bypass
urgery, including reductions in periprocedural morbidity
nd mortality. However, concerns remain regarding clini-
ally important patient benefits, long-term durability, and
ates of reintervention associated with percutaneous treat-
ent strategies. The rapid proliferation of new technolo-
ies has left the vascular specialist with an array of potential
herapies to treat PAD, often without rigorous outcome
ata or cost-efficacy information to guide responsible treat-
ent decisions.
These issues have gained special relevance since the
atient Protection and Affordable Care Act was signed into
aw in 2010 in concert with the implementation of other
nitiatives to “bend the curve” of rising health care costs. In
his context, comparative effectiveness research (CER) has
eceived increased attention. The United States Congress
as appropriated $1 billion to support this national ini-
iative, while asking the Institute of Medicine to identify
riority topics. Lower extremity PAD has been identified as
ne of these priorities.2
The Society for Vascular Surgery (SVS) strongly
ndorses the use of CER to completely evaluate the
vailable options for the treatment of PAD.3 The pur-
ose of the present report is to review and describe the
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October 20111132 Moriarty et alcurrent literature regarding economic evaluations of en-
dovascular and open treatment alternatives in patients
with lower extremity PAD.
METHODS
A systematic review was conducted following a proto-
col established a priori and according to the recommenda-
tions of the Cochrane Collaboration and reported using the
relevant items from the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA).4,5
Eligibility criteria. Eligible studies were (1) original
comparative studies that (2) included an economic or cost
analysis of (3) endovascular vs surgical interventions for
revascularization in patients with PAD presenting with
intermittent claudication and critical limb ischemia (CLI).
We included studies regardless of size, date of publication,
follow-up length, language, or design. The eligibility crite-
ria were inclusive of nonatherosclerotic disease processes,
although the final selection of economic and cost articles
included only atherosclerotic disease patients.
Literature search. The initial search strategy was de-
veloped on Ovid MEDLINE (1950-September 2009) and
applied to the databases as noted in the Appendix (online
only) using a combination of medical subject headings
(MeSH), subheadings, and text words. The subject head-
ings peripheral vascular diseases (expanded to include all
related terms), arterial occlusive diseases, arteriosclerosis or
thromboangiitis obliterans, and intermittent claudication
were augmented with textwords such as “peripheral angi-
opathy,” PVD or PAD or PAOD, leg or limb ischemias,
critical or threatening limb or leg injury, as well as specific
vascular terms (eg, inguinal, saphenous, femoropopliteal).
The economics concept also used a combination of subject
headings economics/or cost and cost analysis/subheadings
(economics attached to various procedures), and textwords
such as cost, reimbursement, saving, money, dollar, and
“cost-effective.” The final concept was the treatments of
interest, physical therapy modalities, vascular surgical pro-
cedures, and angioplasty techniques. The detailed strate-
gies are available in the Appendix (online only). We also
reviewed references of included studies and contacted ex-
perts on comparative effectiveness from the SVS to obtain
additional references. The references from the experts were
used to benchmark the search strategy’s comprehensive-
ness.
Study selection and data extraction. Two reviewers
working independently reviewed all abstract and titles, and
potentially eligible studies were selected for full-text assess-
ment. The abstract reviewers erred on the side of inclusion,
and all disagreements at this stage were included for evalu-
ation of the full-text report. Reviewer pairs had adequate
chance-adjusted inter-reviewer agreement in assessing the
eligibility of full text articles using the inclusion and exclu-
sion criteria described above ( statistic 0.72). Disagree-
ments at the full-text stage were resolved by consensus or
arbitration.
Data extraction was always confirmed by a second
reviewer. Our data collection approach followed the sug- destions made by Pignone et al.6 We extracted data
escribing patient demographics, surgical procedures,
tudy design (randomized controlled trial, observational,
odel-based, other), clinical outcome unit (quality-
djusted life-years [QALY], life-years, etc), cost measure-
ent and perspective (charges, payer cost, provider cost,
ocietal cost), and adjustment methods (future cost dis-
ount, retro-inflation, inflation year).
Analysis. Although a meta-analysis of cost-effectiveness
tudies would have been desirable to estimate pooled cost-
ffectiveness ratios, these studies were scant, and their results
ere inconsistent in methods and findings, which limited the
alue of pooled estimates. Thus, the analyses presented in this
eport focus on describing the results of the included studies
cross the three categories suggested by Drummond et al7
Table I).
ESULTS
Search results. The literature search, supplemented
y references provided by content experts from the SVS,
ielded 1351 references. After title and abstract screening,
2 references were deemed eligible and were retrieved for
ull-text screening. Of these, 19 met criteria to be included
n the analysis.8-26 A detailed schematic of the search results
s depicted in the Fig. The number of suitable studies was
elatively scant, and as a result, claudication andCLI studies
ere considered together in an attempt to identify signifi-
ant trends and patterns in the literature.
Study type and quality. Table II presents a summary
f the included studies by study type (model-based decision
nalysis, econometric cost-analysis, or a cost-consequence
nalysis). Table III describes all included studies. Of the 19
tudies, 12 were cost-consequence studies reporting at least
ne clinical outcome as well as an economic outcome, 11
ompared open surgery with endovascular treatment, and
he remaining 7 included additional treatment approaches.
he most common perspective (14 studies) was of the
ealth care provider, which only looks at direct costs to the
eath care institution. The remaining four studies used a
ocietal perspective, which includes all costs to society
egardless of who actually incurs them. All but one study
sed patient-level direct costs in the analysis.
Nine studies did not use any type of sensitivity analysis.
odel-based studies used the most robust approaches to
ensitivity analyses. All other studies that performed sensi-
ivity analyses primarily did so by using subgroup analyses
r by including different types of costs. Nine studies gave
o details or offered incomplete information about the
pproach to adjust for inflation and discounting.
Model-based studies. Model-based studies include
ll those that pool retrospective data and use statistical
ethods to derive outcomes. The modeling studies were
he most homogeneous in study design,11,13,19 offered the
ongest time horizon (5 years in 1 and lifetime horizon in 2
tudies), used QALY as the clinical outcome, and used
quivalent clinical and economic outcome time horizons
ithin each study. All these studies found no dominant or
ominated treatment strategy. Furthermore, two of the
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Volume 54, Number 4 Moriarty et al 1133three studies found that the optimal strategy in the incre-
mental cost–effectiveness ratio was sensitive to indica-
tion.13,19 In these studies, catheter-based therapy was more
cost-effective or provided greater net health benefits in
patients with claudication, whereas initial bypass was most
cost-effective or provided the greatest limb salvage benefits
in patients with CLI. The inconsistency in results across
these studies suggests that the optimal strategy, in both
patient benefits and costs, may depend on patient charac-
teristics, lesion anatomy, degree of ischemia, procedural
technique, and perioperative care, the latter 2 of 10 related
to learning curves, teamwork, and procedural volume.
However, these features were not sufficiently described in
the study reports.
Cost-analyses studies. These studies only focus on
economic outcomes. Two of the four cost-analyses studies
compared endovascular techniques with open surgery,
whereas the other two included amputation as a third
Table I. Summary of analysis types, with pros and cons
Analysis type Description
Model based An analytic representation of the
problem at hand that uses
previously reported data as
model inputs
● A
● L
t
● A
b
● A
c
s
Econometric cost
analysis
An appraisal that uses quantitative
and statistical methods to
analyze economic outcomes
only and not clinical outcomes
together
● S
● E
Cost consequences An appraisal that reports both
economic and at least one
clinical outcome together
● R
c
t
t
s
a
Fig. Schematic of searchcomparator.10,15,20,24 Only one study20 used a societal eerspective. This study was also unique in that the authors
sed macro-level cost data for the analysis, estimating the
osts at a national level and then imputing costs per patient.
he main outcome of the cost analyses was consistent
cross all studies and showed the endovascular approach
as the least costly in the short-term.
Cost-consequence studies. Although there were some
imilarities, the studies conducting a cost-consequence analy-
is were heterogeneous in their measurement of costs and
utcomes.5,8,9,12,14,16-18,21-23,25,26 Five studies focused on
atency, amputation-free survival, or overall mortality. QALY
as the only outcome in one study. Patency, length of stay,
nd death were the outcomes in the other six studies. Six of
he 12 studies had a time horizon for the clinical outcome of
1 year (including surgical episodes only). Five of the remain-
ng studies used a time horizon between 1 and 5 years.
onversely, only three studies had a time horizon for cost data
1 year. Five studies only assessed the costs of the surgical
Pros Cons
tic flexibility
ostly/time-consuming
linical trials
ailable information can
thesized together
certainty in model inputs
e taken into account
taneously
e to perform
understandable
● Does not allow for a complete
picture needed for informed
decision making
rting both economic and
l outcomes allows for
ility to represent poten-
ade-offs of changing from
ard of care to a new
ach
● Trade-offs may be abstract and
difficult to judge “a good
trade”
lts and study selection.naly
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October 20111134 Moriarty et aloutcomes and costs in 7 of the 12 studies, and the remaining
5 measured costs in a shorter time horizon than the clinical
outcomes.
For clinical outcomes, three studies favored surgery and
seven favored endovascular revascularization, whereas two
other studies did not report outcomes separately for the
two procedures. All studies used patient-level direct data,
presented the results from the health care provider perspec-
tive, and found the endovascular approach was the least
costly. Closer inspection of these studies suggests that only
three offered results of importance, insofar as they assessed
patient important outcomes (quality-adjusted time without
symptoms of disease or toxicity of treatment, QALY, years
of leg saved, and death) and considered cost and outcome
horizons of 1 year.14,17,23 These three studies, of which
only one considered a time horizon of 5 years, suggest
similar clinical outcomes across procedures but lower costs
with endovascular approaches.
DISCUSSION
Main findings. Although this review provides in-
sight into the current status of economic evaluations of
the invasive treatments of PAD, the limitations of the
data provide few meaningful conclusions about the eco-
nomic ramifications and, more importantly, the cost-
effectiveness of different treatment options. Endovascu-
lar therapy appears to be the least costly option in the
short-term; however, the long-term clinical and eco-
nomic consequences of these procedures remain unclear.
The current cost-effectiveness data in the literature are
relatively coarse (indication dichotomized between CLI
and claudication) and tend to lack anatomic information,
Table II. Summary of included studies group by analysis t
Type of study Treatment comparisons
Model based: 3 studies11,13,19 ET and surgery only: 1 Q
ET, surgery, and
other(s): 2
Cost analysis: 4 studies10,15,20,24 ET and surgery only: 2 N
ET, surgery, and
amputation: 2
Cost consequences: 12
studies5,8,9,12,14,16-18,21-23,25,26
ET and surgery only:
10
P
ET, surgery, and
other(s): 2
Q
L
M
M
ET, Endovascular treatment; ICER, incremental cost-effectiveness ratio; LO
aPatency/amputation-free survival/mortality.detailed patient information, functional status, and latient-centric outcomes. A cost-conscious evidence-
ased decision regarding a patient’s optimal treatment
trategy depends on these factors, which are clearly
acking from the exhaustive review presented in this
eport.
Implications for policy and research. As opposed to
hat we found in many of the studies included in this
eview, economic evaluation studies should pay attention
o indication, anatomy, patient comorbid and functional
rofile, choice of patient-important outcomes, and use of
omparable time horizons for both cost and clinical out-
omes. The available options vary by indication. Studies
valuating patients with intermittent claudication should
onsider endovascular interventions, bypass surgery, as well
s medical and exercise therapy. Studies evaluating patients
ith CLI will have to consider also primary amputation as
n option. Surrogate markers, such as patency and proce-
ural times, which are important perhaps in evaluating the
echnical feasibility of a procedure, at best indirectly inform
he extent to which these procedures offer benefits that
atients value.
These studies should focus instead on patient-impor-
ant outcomes such as health-related quality of life and
unctional capacity (eg, walking distance) in patients
ith intermittent claudication; and limb salvage, death,
nd freedom from major adverse limb events in CLI,27 as
ell as periprocedural events that patients value avoid-
ng, including severe bleeding, limb loss, cardiovascular
vents, and death.
Complete economic evaluations should use compara-
le time horizons for both cost and clinical outcomes to
ppropriately compare their relationship. Because of these
Measurement Time horizon
mes Costs Outcomes Costs
3 Secondary data
sources: 3
Lifetime: 2 Lifetime: 2
5-10 yrs: 1 5-10 years: 1
4 Patient level: 3 NA Surgical episode
only: 2
Macro level: 1 1-5 years: 1
5-10 years: 1
y: 2 Patient level:
12
1 yr: 4 1 year: 4
1 1-5 yrs: 5 Surgical episode
only: 5
5-10 yrs: 1 1-5 years: 3
ity: 2 Surgical episode
only: 2
le: 5a
gth of stay; NA, not applicable; QALY, quality adjusted life-year.ype
Outco
ALY:
one:
atenc
ALY:
OS: 2
ortal
ultipimitations, this review cannot offer clear and strong infer-
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options of interest, a common finding in systematic reviews
of economic analyses.28
The four cost analyses allow us to observe that a ther-
apeutic innovation, such as an endovascular procedure that
reduces the need for hospitalization, also reduces direct
patient costs around the time of the index procedure.
However, these are partial economic analyses because no
assessment of patient outcomes took place. Furthermore, it
is difficult to draw definitive conclusions regarding cost
differences given the differences in time horizons across
these four studies. Also, two of the studies only reported
costs of the surgical episode, potentially missing any costs
due to reintervention.
The cost-consequence studies could overcome some
of the limitations we just discussed. However, only 4 of
the 12 studies included patient-important outcomes,
such as quality of life and amputation-free sur-
vival.8,17,23,25 Furthermore, the inclusion of both costs
and clinical outcomes requires equivalent time horizons
for both of these elements. When the time horizon for
outcomes is longer than the horizon for costs, which
results from difficulties capturing long-term costs, costs
associated with long-term management and reinterven-
tion may be missed, particularly when the initial treat-
ment had limited durability.
Only 9 of the 19 studies reported conducting sensitivity
analyses, the type of which varied importantly.9,11-13,17-20,22
These included subgroup analyses based on patient charac-
teristics and clinical outcomes, one-way and multiway sen-
sitivity analyses of model parameters, and the exclusion of
certain costs such as professional fees and those not occur-
Table II. Continued.
Outcome and cost
horizons
equivalent Cost perspective Outcome results
Yes: 3 Societal: 1 Surgery preferred: 1
Health care
provider: 2
Dependent on patient
characteristics: 2
NA Societal: 1 None: 4
Health care
provider: 3
Yes: 7 Societal: 2 Surgery preferred: 3
No (cost timeline
shorter): 5
Health care
provider: 10
ET preferred: 7
Indeterminable: 2ring during the surgical procedure. In general, sensitivity mnalyses had no effect or showed results that favored endo-
ascular treatment.
Model-based studies enable analysts to consider many
evels of uncertainty (Table I). The assumptions of the
hree model-based studies are not identical, but they are
airly similar. None suggest a dominant endovascular or
pen surgical strategy that is appropriate for all patients.
he two studies that used the health care provider perspec-
ive had similar conclusions, although through different
ssumptions.13,19 Both studies found endovascular treat-
ent was optimal or cost-effective for most patient indica-
ions and lesion types; bypass surgery was optimal for
atients with rest pain or tissue loss and for those presenting
ith occlusion, regardless of graft type. However, the study
y Hunink et al13 found an endoluminal strategy was
ptimal for certain patients with stenosis. This strategy was
ot included in the Muradin et al19 study. The final model-
ased study found that drug therapy, a treatment approach
nique to this study, had the lowest cost per QALY.11
owever, this study also found that all approaches were
ost-effective with the baseline comparator approach of no
reatment.
Future work reporting economic analyses would bene-
t greatly from following guidelines recommended by the
nternational Society of Pharmacoeconomics Outcomes
nd Research.29,30 Specifically, research performing sensi-
ivity analyses with varying time horizons could help iden-
ify interactions between cost-effectiveness and time. If this
ere the case, treatment by patient and anatomic charac-
eristics could be tailored more appropriately. However,
ubgroup analyses are seldom reliable, and systematic skep-
icism should be exercised.31 Such research should opti-
Dominant or
dominated
strategiesCost results ICER results
reatment
ferred: 1
Drug therapy, followed
by no treatment
preferred: 1
Dominant
strategies: 0
ndent on patient
aracteristics: 2
Dependent on patient
characteristics: 1
Dominated
strategies: 0
PTA: 1
referred: 4 NA NA
referred: 12 ET dominant: 7No t
pre
Depe
ch
ET p
ET pally focus on patient-important outcomes such as disease-
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First author (year)
Patients (n; age)
procedures Study design Cost analysis methods Outcome
Cost
perspective
Adjustment
method Outcomes
Model-based
Hunink13
(1995)
Fem-pop disease
amenable to
PTA or BS,
(NR, 65)
Markov
model
A two-staged treatment
approach is used
based on the PTA,
bypass, or no
treatment. Strategies
include no
treatment; no
treatment, PTA; no
treatment, PTA-PTA
PTA-bypass, bypass;
no treatment, and
bypass-bypass. Cycle
time not explicitly
given but appears to
be 1 year long.
QALY Health care
provider
1990 US$ QALYs based
on values of
health states
derived from
the Torrance
Multi-Attribute
Scale.
Muradin19
(2001)
Fem-pop arterial
disease. Base
case (NR, 65-
yo man).
Bypass vs
PTA vs
hypothetical
ET
Markov
model
PTA vs BS vs
hypothetical ET
device. Assumed
willingness to pay
for 1 QALY
$20,000.
QALY Health care
provider:
costs
1999 US$ Health state
QALYs were
estimated using
an abbreviated
form of the
Health Utilities
Index.
Holler11
(2006)
Drug therapy,
ET, BS, or
NT (NR, 65)
Markov
model
A two-staged
treatment approach
based on the 4
options resulting in
16 differing
treatment strategies.
1-year Markov cycles.
QALY Societal 2001, 5%
discount
rate
Life expectancy
and QALYs
generated for
all treatment
options.
Cost analysis
van Dijk24
(1997)
ET (35; age 71)
vs BS (38; age
71)
RCT DUCC None, cost
analysis
only
Health care
provider
1994 Dutch
guilder,
converted
to US$
None given
Eneroth10
(1996)
BS (96, age
NR), ET
(111, age
NR); or
amputation
(114, age
O–R DUCC, also
segmented between
cost categories
None, cost
analysis
only
Health care
provider
1996 Hospital days
are not given
by surgical
group, little
to go on.NR)
JOURNAL OF VASCULAR SURGERY
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Time horizon Costs included Sensitivity analysis
Cost
unit Outcomes Cost results ICER
Life-time
costs,
simulated
until entire
cohort had
died
Hospital and
physician costs
for initial and
secondary
procedures, follow-
up, amputation
and rehabilitation,
and long-term care
One-way sensitivity
analyses and multiway
sensitivity analysis
(simultaneous change
in all treatment
variables to a
favorable direction).
Sensitivity analyses
based on $50,000 per
QALY threshold.
US$ Results based on
indication and
stenosis/
occlusion;
overall figures
not given.
Results based
on indication
and stenosis/
occlusion;
overall figures
not given.
For patients with stenosis
or with an occlusion
and disabling
claudication: initial
PTA increased
effectiveness and saved
lifetime expenditures vs
BS, PTA; PTA always
dominant vs NT;
PTA-BS increased
effectiveness further for
some, most ICERs
$50,000 per QALY
gained. In patients
with an occlusion and
chronic critical
ischemia: initial BS
yielded the highest
effectiveness and was
cost-saving or cost
$2000 per QALY
gained vs NT.
Life-time
costs,
simulated
until entire
cohort had
died
Treatment cost
related to disease
(initial/subsequent
procedures, tests
for follow-up,
routine
examinations,
amputation and
rehabilitation,
annual costs of
amputation or
major morbidity).
One-way sensitivity
using age, sex,
willingness to pay,
discount rate, risk of
hypothetical device
(morbidity mortality,
time lost). Age, sex,
willingness to pay,
and device risk used
in 4-way sensitivity
analysis.
US$ BS highest NHB
for patients
with chronic
critical
ischemia and
occlusion,
PTA highest
NHB in
stenotic fem-
pop lesions.
Highest
QALYs
achieved by
PTA.
PTA costs range
$22,758-
$65,578
depending on
indication;
bypass cost
range
$33,229-
$53,346
depending on
indication.
Reported as net health
benefits with assumed
society willingness to
pay. PTA had higher
net health benefits than
bypass in most, but not
all indications.
5 years, both
outcomes
and costs
Direct and indirect
costs from a
societal perspective
by health state
based on survey
data. No more
details given
beyond this.
One-way sensitivities
of  10% of
transition
probabilities.
€ BS/BS option
most effective
(1.838
QALY); NT/
NT least
effective
(0.802
QALY)
BS/BS most
costly
(10,420.10
average total
costs); NT/
NT least
costly
(5941.80
average total
costs)
Lowest ICER ($2321.21)
is achieved with the
drug therapy/NT
strategy; highest ICER
($12,522.50) is
achieved with the NT/
BS. NT/PTA, drug
therapy/PTA, PTA/
PTA, BS/PTA, drug
therapy/BS, PTA/BS
all dominated by
another strategy having
the same first-line
treatment.
Short-term,
surgical
episode
only
Direct costs from
hospital episode;
operation costs,
postop care,
treatment of AV-
fistulae
None US$ None ET, $6322; BS,
$8030
No clinical outcomes,
cannot be calculated
6 years or
until death
(details on
postsurgical
episode
costs very
Direct patient costs
from hospital
episode,
rehabilitation clinic
and nursing home
costs
None US$ None BS, $46,000;
ET, $41,000;
amputation,
$54,000
No clinical outcomes,
cannot be calculatedvague)
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First author (year)
Patients (n; age)
procedures Study design Cost analysis methods Outcome
Cost
perspective
Adjustment
method Outcomes
Myhre20
(1998)
BS (46; age 72)
vs amputation
(44; age 75)
vs PTA
(extrapolated
data)
O–R DUCC, costs reported
on an annual basis,
by procedure and
national estimates.
None, cost
analysis only
Societal 1996 US$ None given
Jansen
(1998)15
Occlusive PVD,
(age 65.6).
BS (487) vs
PTA (96)
O–P Multiple linear
regression analysis,
DUCC
None, cost
analysis only
Health care
provider 
costs
1995 US$ NR. LOS used
as an
explanatory
variable. One
table gives
LOS for
certain groups
of patients but
does not
match
previous
grouping.
Cost
consequences
Stoner22
(2008)
BS (183; age
63.9) ET
(198; age
66.0)
O–R Amortized cost model
to calculate cost per
day of patency at any
given time.
Patency Health care
provider
NR Patency is
compared
using KM
curves.
Adam (2005)8 ET (224, 70:
30%, 70-79:
46%, 80:
24%) BS
(228: 70:
35%, 70-79
39%, 80
26%)
RCT Unadjusted inpatient
costs per day
Amputation-free
survival, all-
cause
mortality,
utility
(EuroQuol
5D and SF36
Health care
provider
Inflated to
FY 2003-
04
Morbidity,
additional
treatments,
KM survival
curves, HRQL
Whatling26
(2000)
BS (87; age
67.9), ET
(51; age
61.9)
O–P DUCC Patency Health care
provider
NR Patency is
compared
using KM
curves.
Singh21
(1996)
BS (52), ET
(52),
amputation
(46; overall
age 71
O–P DUCC, median costs
reported
Mortality Societal NR 1-year mortality
percentage
reported by
group.
Jeans16
(1986)
BS (13), ET
(11)
Not specific
but
appears
to be
DUCC on a subset of
patients
LOS Health care
provider
1984
costing
year
Mean LOS,
descriptive
only, no
statistical testO–R performed.
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Time horizon Costs included Sensitivity analysis
Cost
unit Outcomes Cost results ICER
1 year Procedure costs,
medical treatment,
and nursing home
stays
Different
reimbursement
approaches used for
sensitivity analysis.
US$ None BS $6971 per
patient, $5.23
million
nationally;
amputation
$21,200 per
patient,
$16.77
million
nationally,
PTA $1855
per patient,
$740,000
nationally
No clinical outcomes,
cannot be calculated
Short-term,
surgical
episode
only
All costs of surgical
episode except
physician fees
None US$ None Weighted costs
calculate to
BS, $19,008;
PTA,
$10,356
No clinical outcomes,
cannot be calculated
12 months Initial surgical
episode (direct and
indirect), adverse
events postsurgery
Subgroup analyses
based on clinical data
and outcomes.
US$ ET patency,
78%; BS, 66%
BS, $12,389;
ET, $6739
Open surgery: $229/day
of patency; ET: $185/
day of patency
12 months,
both costs
and
outcomes.
High rates
lost to
follow-up
12
months.
Inpatient hospital
direct costs
None British £ BS 1-year
amputation-
free survival:
68%; ET 1-
year
amputation-
free survival:
71%
BS, 23,322; ET,
17,419
NR. ET would
dominate.
Outcomes up
to 6 years,
short-term
for costs
(intervention
only)
Inpatient hospital
direct costs
None British £ BS patency: 99%;
ET patency:
68% (at 6
years)
BS, 3072; ET,
1912
NR. A break-even point
of percentage of ET
failing (48%) is
calculated.
1 year, both
mortality
and costs
Direct patient costs
of initial
hospitalization,
selected follow-up
costs, some patient
out-of-pocket costs
None British £ ET: 25.0%
mortality; BS:
23.1%
mortality;
unilateral
amputation:
32.4%
mortality;
bilateral
amputation:
33.3%
mortality.
ET, 5443; BS,
6766;
unilateral
amputation,
10,162;
bilateral
amputation,
13,848
NR. No difference in
clinical outcomes,
simplifies to a cost
minimization analysis.
Short-term,
surgical
episode
only
Direct patient costs None British £ Greater LOS for
BS patients
(13.7 vs 2.8)
Surgical, 1328;
dilatation,
301
NR. ET would dominate.
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First author (year)
Patients (n; age)
procedures Study design Cost analysis methods Outcome
Cost
perspective
Adjustment
method Outcomes
Sultan
(2009)23
PTA (190; age
73), BS (119;
age 70)
O–P DUCC, total group
costs reported,
average costs
reported based on
procedure number
(includes repeats)
Q-TWiST,
QALY
Health care
provider
NR QOL analysis
uses Q-TWiST
to calculate
QALYs.
Laurila
(2000)17
PTA (86; age
70.3) or BS
(38; age 73.7)
O–P DUCC Reoperation-free
years and year
of leg saved
Health care
provider
Converted
from
Finnish
marks to
US$, year
not
explicitly
given,
appears to
be 1994
KM curves for
patency rates,
reoperation-
free cases, and
leg salvage
rates
Hunink12
(1994)
Fem-pop PTA
(71; age 64.6)
vs BS (228;
age 66.4)
O–P Multiple linear
regression analyses
using stepwise
selection
LOS Health care
provider
1990 US$ LOS only
outcome used.
Same analysis
used as for
costs. Wald
test used for
significance.
Mertens18
(2005)
Infrarenal
arterial
stenoses (n,
age NR). 442
episodes for
343 patients:
surgical 221,
ET 199,
mixed 22)
O–R DUCC Mortality, LOS Societal NR KM curves for
survival,
descriptive
comparison
for LOS,
multivariate
regression
performed on
amputation-
free and
reintervention-
free survival.
Ballard9
(1998)
Severe aortoiliac
occlusive
disease. ET
(65; age 67),
BS (54; age
64)
O–R DUCC, Student t test
performed.
Survival and
primary
patency
Health care
provider
NR KM curves for
survival and
primary
patency. No
significant
difference in
survival.
J. d’Othée14
(2008)
Intermittent
claudication
due to
aortoiliac
and/or fem-
pop disease.
ET (64; age
62.7), BS (33;
age 63.6)
O–R Univariate and
multivariate analysis
(log transformation)
using direct and
indirect costs from a
cost accounting
system, descriptive
unadjusted as well.
Primary
outcome is
cost. Multiple
clinical
outcomes,
including
patency and
mortality
Health care
provider 
direct and
indirect
costs from
a cost
accounting
system
NR P values only
listed for those
that are
significant (NS
for all others).
KM curve
given for
follow-up
duration.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 4 Moriarty et al 1141Table III. Continued.
Time horizon Costs included Sensitivity analysis
Cost
unit Outcomes Cost results ICER
5 years, both
outcomes
and costs
Direct patient cost of
inpatient events
only, includes
initial treatment.
None € QALY– PTA,
2.058; BS,
2.042
PTA, 12,637;
BS, 20,142
(manually
calculated)
NR. PTA would
dominate.
3 years, both
outcomes
and costs
Hospital costs,
including initial
operation and 3-
year follow-up.
Specific costs
include hospital
stay, ICU stay,
radiologic exams,
and operations.
Subgroup analyses
based on occlusion
length (under 10 cm
and under 15 cm).
US$ 3-year patency:
BS 52%, PTA
45%; 3-year
reoperation-
free cases: BS
68%, PTA
56%, 3-year
leg salvage
rate: BS 90%,
PTA 79%. No
significant
differences
found in any
outcome
measure
PTA $8855;
surgery
$16,470
Cost per reoperation-free
year: PTA $4466;
surgery $7418. Cost
per leg saved: PTA
$3877; surgery $6055.
Short-term,
surgical
episode
only
Costs for primary
episode. Physician
fees were excluded.
Subgroup: patients with
1 admission during
the study time period
US$ BS resulted in an
(adjusted)
increase in
LOS of 6.3
days (P 
.0004)
BS resulted in
an (adjusted)
increase in
costs of
$5038 (P 
.006)
NR. Adjusted ICER
$799.68 per hospital
day (BS dominated).
Outcomes up
to 5 years
after
procedure,
cost analysis
30 days
before
intervention
to 6 weeks
after
“Total health
insurance costs”:
physician fees for
main procedure,
charges for hospital
stay, ET devices or
grafts, drugs,
anesthesia, x-rays,
laboratory tests,
other fees/costs
Subgroup analysis of
selected anatomic site
of procedure
€ 95% of patients
70 years
survived 4
years, 70-79
had 80%
survive 4
years, half of
the patients
80 years
died 6
months.
Surgical: $4437;
ET by
surgeon:
$3643; ET by
radiologist:
$2358
NR. Only can be done
using cost per median
LOS for BS ($369.75),
ET by surgeon
($910.75), ET by
radiologist ($2358).
Up to 46
months for
outcomes
(mean, 22
months),
costs are
short-term
(hospital
episode
only)
Costs for surgical
episode
Re-ran analyses
excluding
professional fees and
for only direct
procedure costs
US$ ET survival
97% by 24
months, BS
survival 90%
by 24 months.
Significant
improvement
of primary
patency for BS
vs ET at 18
months (P 
.002).
Mean hospital
costs,
including
professional
fees: ET
$9161; BS
$10,585. No
difference
statistically,
including
sensitivity
analyses.
NR. Time periods not
consistent. Raw data
for main outcome
variable (survival) not
reported.
Not specific.
Mean
follow-up–
ET, 941
days;
surgical,
1138 days.
Cost and
outcome
time frame
appear to be
the same.
Initial surgical
episode (direct and
indirect),
outpatient and
inpatient costs
during follow-up
None US$ 1-year patency:
ET 94%;
surgery 95%.
“Late”
mortality: ET
9.4%; BS
15.2%
Total costs: ET
$11,849; BS
$15,577.
Multivariate
analysis found
ET approach
had 25%
reduction in
costs, all else
equal.
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measures in claudication, andmajor adverse limb event-free
survival in CLI.
Strengths and limitations. Because of the relatively
small data set to work with, we were obliged to accept
several notable limitations with respect to inclusion criteria:
First, we included series that examined nonatherosclerotic
disease processes. Still, almost all of the studies presented
represent atherosclerosis patient populations.
Second, we did not separate claudication from CLI.
Again, this compromise was made because of the small
numbers and lack of separation seen in many of the eco-
nomic studies examined. We acknowledge that these are a
heterogeneous group of studies, with different treatment
indications and outcome measures, such as patency, limb
salvage, and functional status. This glaring issue should be
addressed in future studies through adherence to reporting
standards and provision of accepted objective measures of
limb ischemia.
This review has several other notable limitations. Nine
of the 19 eligible studies were published10 years ago, the
oldest was published 23 years ago, and modeling studies
also had to rely on older data. Outdated evidence threatens
the applicability of our findings. Unfortunately, the scarcity
of studies precluded performing a sensitivity analysis based
on data “vintage.”
Lack of data precluded economic analyses of reinter-
ventions. The inclusion of both claudication and CLI stud-
ies, because of the scant literature, introduced inconsis-
tency into the review.
Publication bias and inconsistency across studies also
threaten the validity of the conclusions of this report.
Inconsistency in approach, model assumptions, choice of
options, outcomes of interest, and source and quality of
data for clinical and cost outcomes, and actual variation
Table III. Description of included studies
First author
(year)
Patients (n; age)
procedures Study design Cost analysis met
Werneck25
(2009)
CLI, high
operative risk
(age 69). BS
(32) vs PTA
(45; only 26
used for cost
analysis)
O–R DUCC, nonparam
Mann-Whitney
test.
BS, Bypass surgery; CLI, critical limb ischemia; DUCC, descriptive unad
health-related quality of life; ICER, incremental cost-effectiveness ratio; IC
benefit;NR, not recorded;NT, no treatment;O–P, observational prospectiv
PVD, peripheral vascular disease; QALY, quality-adjusted life-year; QOL,
toxicity of treatment; RCT, randomized controlled trial; SF36, Short Formin cost structure (ie, hospital costs, professional fees, teimbursement rates and other determinants of cost vary
cross health systems and countries) limit the compara-
ility of and the ability to meta-analyze the available
ata.
Finally, the review was commissioned by the Society
or Vascular Surgery and several of its members were
uthors of this report. A rigorous protocol of review to
hich we adhered sought to limit the introduction of
oints of view that may have favored one or the other
ntervention.
The strengths of this report stem from the comprehen-
ive literature search, a priori established protocol and
nclusion criteria, and bias protection measures undertaken
uring the conduct of this review, including selection of
vidence by pairs of nonconflicted reviewers working inde-
endently.
ONCLUSIONS
We found only very low quality evidence (ie, studies
ith major methodologic limitations, including incon-
istent and brief time horizons, narrow selection of treat-
ent options and outcome measures, poorly reported,
cant, potentially outdated, and inconsistent in their
ethods and results) providing economic inferences
bout the relative merits of endovascular and open sur-
ical approaches to the treatment of PAD patients.
herefore, any inferences are weak and are likely to
hange with new research.
Although endovascular procedures appear less costly
n the short-term, long-term comparison between cath-
ter-based procedures and open revascularization in cost
nd patient-centric outcome remains uncertain. In addi-
ion, more data need to be analyzed to assess the role of
ffective nonoperative therapies (eg, drugs, exercise)
Outcome
Cost
perspective
Adjustment
method Outcomes
Amputation-free
survival and
overall survival
(only appears
to be for PTA
patient)
Health care
provider 
costs
NR KM curves but
only for
overall
survival.
cost comparison; ET, endovascular treatment; FY, fiscal year; HRQL,
ensive care unit; KM, Kaplan-Meyer; LOS, length of stay; NHB, net health
, observational retrospective; PTA, percutaneous transluminal angioplasty;
of life; Q-TWiST, quality-adjusted time without symptoms of disease or
m survey; US$, United States $.hods
etric
U
justed
U, int
e;O–Rhat may produce clinical benefit at lower costs and may
11
1
1
1
1
1
1
1
1
2
2
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treatments.
Additional research is needed to investigate the uncer-
tainties of cost-effectiveness of PAD treatment. Such re-
search should optimally focus on patient-important out-
comes such as disease-specific and overall quality of life,
functional ambulatory measures in claudication, and major
adverse limb event-free survival in CLI. The current state of
the data and literature underscore the importance of pro-
fessional society-backed database efforts and mandate that
cost and durability be accounted for as new technologies
are assessed. Furthermore, vascular journal editorial boards
should mandate that all reports follow standard reporting
guidelines to allow for appropriate comparative economic
analyses.
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Volume 54, Number 4 Moriarty et al 1144.e1Appendix: (online only). Search strategy
MEDLINE (1950-2009) October week 4
EMBASE (1988-2009) week 45
Adj  adjacent terms (adj3  within 3 words)
Exp explode, expand to include all terms in subhierarchy
/ec  subheading economics
/subject heading, either MeSH or EMTREE
.fs. floating subject heading (applied anywhere in subject
headings)
.mp.  title, original title, abstract, name of substance
word, subject heading word, unique identifier
*or $wild card truncation
1. exp Peripheral Vascular Diseases/ec [Economics]
2. arterial occlusive diseases/or arteriosclerosis/or exp
thromboangiitis obliterans/
3. arterial occlusive diseases/ec or arteriosclerosis/ec or
exp thromboangiitis obliterans/ec
4. 1 or 3
5. 4 and su.fs.
6. vascular surgical procedures/ec or angioplasty/ec or
blood vessel prosthesis implantation/ec or stents/ec
or “tissue and organ harvesting/ec”.mp. [mptitle,
original title, abstract, name of substance word, subject
heading word, unique identifier]
7. exp physical therapy modalities/ec or amputation/ec
or occupational therapy/ec
8. angioplasty, balloon/ec
9. exp “costs and cost analysis”/or exp economics, hos-
pital/or exp economics, medical/or exp “fees and
charges”/
10. length of stay/or hospital costs/or models, econom-
ic/or postoperative complications/ec
11. life expectancy/or absenteeism/or http://employ-
ment.mp. or http://unemploy*.mp. or recovery of
function/or return to work/[mp title, original title,
abstract, name of substance word, subject heading
word, unique identifier].11. life expectancy/or absen-
teeism/or employment.mp. or unemploy*.mp. or re-
covery of function/or return to work/[mptitle,
original title, abstract, name of substance word, subject
heading word, unique identifier]
12. Quality-Adjusted Life Years/
13. (pvd or pad or paod).mp. or peripheral vascular dis-
ease/or intermittent claudication/or claudicat*.mp
. or ischemia/or ischaem* [mptitle, original title,
abstract, name of substance word, subject heading
word, unique identifier]
14. ((peripheral or femoropopliteal) adj3 angiopath*).mp
. [mptitle, original title, abstract, name of substance
word, subject heading word, unique identifier]
15. ((leg or limb) adj2 (ischemi* or ischaemi*)).mp
. [mptitle, original title, abstract, name of substance
word, subject heading word, unique identifier]
16. ((critical* or threaten*) adj3 (limb* or leg*)).mp
. [mptitle, original title, abstract, name of substance Lword, subject heading word, unique identifier] [mp
title, original title, abstract, name of substance word,
subject heading word, unique identifier]
7. saphenous vein/su, tr or femoral vein/su, tr or femoral
artery/su, tr or popliteal artery/su, tr or inguinal ca-
nal/su, tr or exp leg/bs
8. or/13-16
9. (angioplast* or catheteris* or catheriz* or translumi-
nal* or percutaneous* or endovascular* or revascular*
or stent* or blood vessel prosthesis/or blood vessel
prosthesis implantation/or exercise therapy/or resis-
tance training or walking*).mp. [mptitle, original
title, abstract, name of substance word, subject head-
ing word, unique identifier]
0. 18 and (19 or 17)
3. exp Venous Insufficiency/ec [Economics]
4. exp Reoperation/ec [Economics]
5. ((open or bypass or reconstruct*) adj3 (surger* or
surgical* or repair*)).mp. [mptitle, original title,
abstract, name of substance word, subject heading
word, unique identifier]
6. 18 and 25
7. restenosis/ec or treatment failure/ec or graft fail-
ure/or graft occlusion, vascular/ec
8. ((clinical or cost) adj3 effective*).mp. [mptitle, orig-
inal title, abstract, name of substance word, subject
heading word, unique identifier]
9. 3 or 6 or 7 or 8 or 23 or 24 or 27 or 28
0. or/9-12
1. (18 and 25) or 20
2. (29 or 30) and 31
eb of Science 1993-2009
his is a text word database, and does not use subject
eadings.
8 423 #5 NOT #6
efined by: Topic(surgery OR surgical OR revascular*
R angioplast* OR stent* OR endovasc* OR bypass* OR
rosthe* OR reoperat* OR reconstruct* OR repair* OR
esteno* OR surgical* OR postoperative* OR operative*
R salvag* OR endolumin* or amput* OR treat* OR
onservat* OR intervention* OR graft*)
3 847 Topic(“venous insufficien*” OR “vascular insuf-
cien*” OR “arterial insufficien*” OR “peripheral occlu-
ive” OR “peripheral vascular” OR “peripheral arterial”
R claudicat*OR ischaem*OR ischem*OR ulcer*) AND
opic(leg* OR limb* OR femoral OR femoropopliteal
R “femoro-popliteal” OR infrainguinal OR inguinal OR
lower extremity” OR popliteal OR infrapopliteal) AND
opic(cost OR costs OR saving* OR financ* OR money
R economic* OR reimburse* OR outcome* OR risk*
R “length of stay” OR “quality of life”)
efined by: Topic(comparative* OR cohort* OR ran-
om* OR multicent* OR compare OR compari* OR rate
R survival OR disease free OR “disease free”) AND
anguages(ENGLISH).
